Contents


    Executive Summary

    A medical device is an instrument, apparatus, material, or similar entity intended for use in the diagnosis, treatment, cure, or prevention of disease. Claims against manufacturers and distributors of medical devices, and the medical professionals who prescribe and utilize them, have been around for years. Advances in technology, however, have led to a significant increase in the number and types of devices used, resulting in new causes of action and theories of liability. (Re)insurance issues arise in the areas of product liability and cybersecurity coverage.

    Background

    Medical devices have expanded our ability to treat physical ailments with modern technological advances. The Food and Drug Administration (FDA) has commented on the number of new products now generally part of a medical practice. Some products are used externally, such as continuous positive airway pressure therapy (CPAP) machines, glucose meters, nebulizers, portable ultrasounds, walkers, and many others. Other products are implanted into patients to fortify or replace faulty bodily processes. While medical devices have evolved over time to become more efficient and effective, the products are not without safety risks, particularly implanted medical devices, some of which are described below.

    Stents
    A stent is an expandable wire form that is inserted into an artery or vein to increase blood flow and aid in oxygen delivery throughout the body. One kind of stent releases drugs to prevent both the reclosing of vascular structures and the buildup of scar tissue. Endovascular stent grafts repair abdominal aortic aneurysms (AAA) by reinforcing the aortic wall and reducing the risk of aneurysm rupture. All variations of stents introduce product liability risks related to the invasive implantation involved.

    Defibrillator
    Defibrillators are medical devices used to help restore the heart’s rhythm by way of electrical shock. Defibrillation was first used on a human in 1947 during open chest surgery in which electrified paddles were attached directly to the heart. Subsequent technological advances led to portable machinery capable of restoring a heartbeat. Implantable units have gained favor; these are inserted below the patient’s collarbone with wire leads connected to certain areas of the heart that, once stimulated by electrical shock, usually restore normal heart rhythms. Introduced in 1980, the implantable units demonstrate the successive improvements that have allowed for more effective disease management.

    Pacemakers
    A pacemaker is an implanted medical device that uses electronic impulses to regulate a heartbeat. Unlike the defibrillator, a pacemaker is used to ensure that the heart maintains an adequate pace. After the pacemaker is programmed, it constantly monitors the patient’s heart rate and, when needed, delivers an electronic impulse to regulate rhythm. The first external artificial pacemaker was invented in 1926, and shortly after a portable pacemaker was developed that could keep a heart rate between 80 and 120 pulses per minute. In 1958, the first implantable pacemaker was placed in a human, however several malfunctions made this technology unsafe and ineffective. In response to this, in 1972, manufacturers developed the now-standard pacemaker design which encases the machine in titanium metal. Now manufacturers are working to extend battery life and reduce the size of the unit.

    Infusion Pumps
    Infusion pumps, both implantable and external, administer medication, liquids, nutrients and similar substances throughout the body, normally intravenously. The pumps are available in several styles, including portable pumps, hospital pumps, pumps designed specifically for battlefield use.

    Injuries and Damages

    Medical device risks arise most frequently from product malfunctions, but more recently, data breaches have become a factor in the occurrence of injuries and damages to manufacturers, distributors, and users.

    Device malfunction risk
    All device malfunctions, and complications with medical device side effects, pose the hazard of significant injury to patients and can result in large losses for medical device manufacturers and distributors. Malfunctions present the possibility of injury from lack of rapid treatment or incorrect treatment. For example, infusion pumps that deliver either too much or too little medication could worsen some medical conditions or cause further injuries. Surgically implanted medical devices always present the possibility of complications during implantation such as loss of consciousness, hypoxic brain injuries, respiratory arrest, internal bleeding due to perforated, dissected, or ruptured artery, or death.

    Hacking of medical devices
    As cyber risks increase, analysts have focused on the increasing peril of cyber hacking of medical devices. In May 2017, North Korea managed to hack into medical devices in the US and UK by using stolen ransomware from the NSA known as WannaCry. This attack hacked into unidentified Bayer model devices and prevented medical professionals from accessing these devices. Though there were thankfully no deaths as a result of this attack, some servers were down for almost two weeks resulting in loss of patient information. The total cost of these attacks for the UK’s National Health Service (NHS) alone was estimated to be around £92m.

    Legislation and Regulation

    Medical device manufacturing, labelling, sale, and import are regulated by the FDA’s Center for Devices and Radiological Health (CDRH). In 1976, the federal government made adjustments to the Federal Food, Drug, and Cosmetic Act (FFDCA) with the Medical Devices Amendments, which established three regulatory classes for medical devices entering the market. Similar to the New Drug Application (NDA) for new pharmaceutical drugs entering the market, new medical devices must receive FDA approval on a Premarket Approval Application (PMA) before it is considered safe for sale. Under the FDA Modernization Act of 1997, any changes in medical devices that might affect safety are subject to PMA supplements.

    In order to increase the FDA’s ability to run quality checks on medical devices, the Medical Device User Fee and Modernization Act of 2002 (MDUFMA) was passed. The new amendment implemented a fee for premarket applications, established more definitive regulatory guidelines for devices, and allowed for inspections to be completed by a third-party firm under certain conditions.

    Liability and Insurance

    Medical devices, whether through malfunction, misuse, or faulty design, can result in significant liability.

    Product Liability
    Coverage issues for product manufactures, physicians and hospitals are fairly straightforward; coverage for damages asserted for potential injuries are more complex. Insurance issues are akin to those involving exposure to asbestos in terms of periods of exposure and liability for potential, but as of yet undiscovered, injuries. In addition, further exposure results with respect to the removal and replacement of faulty, or potentially faulty devices, and for associated emotional distress. The potential for multiple coverage issues and the highly technical nature of device-centered litigation increase exposure to defense costs.

    Cybersecurity Coverage
    Medical devices collect and house personal medical information, making manufacturers and venders liable for data breaches and the misuse of medical information. The interaction of medical devices and cyber risk is demonstrated by a case in 2017 in Ohio where state authorities were able to use data from a pacemaker to catch a man committing insurance fraud and arson. When the man told the police that his house spontaneously burned down, cardiologists worked with state authorities to prove that the man intentionally damaged his own property for insurance benefits. The finding was based on inconsistencies between his story and his heart rate as detected by the pacemaker.

    Litigation

    Medical device litigation often involves defective product claims against device manufacturers and distributors as well as professional liability claims against hospitals and physicians. These claims might include a failure to warn of device dangers, breaches of medical device warranties, defective design and manufacture, and violation of consumer protection statutes. In device malfunction situations, the court might order the device maker to perform costly long-term medical monitoring. Litigation against manufacturers might be complicated by the “learned intermediary rule,” which suggests that a manufacturer is not normally required to warn a patient of the dangers of the use of a prescription drug or device; rather, the physician has this responsibility. This rule has been applied where the manufacturer has provided adequate warning to the medical community with the expectation that the patient will receive this information from the doctor. Four cases of interest are described below.

    Rosenberg v C.R. Bard Inc
    The Rosenberg v. C.R. Bard Inc (2019) case sets to determine in Pennsylvania law whether medical devices will be subject to strict liability. Strict liability determines that even in the absence of negligence or intent to harm, a company can still be liable for any damages. Goods like prescription drugs are already considered to be exempt from strict liability given the fact that they are considered inherently dangerous. Rosenberg v. C.R. Bard Inc will decide if medical devices fall under the same category as perception drugs in PA law. This case results from the need for the Plaintiff to receive additional surgeries after she experienced complications from a medical device used in her original procedure. Though the strict liability claims were dismissed by the court for this case, a decision on the overall question of whether medical devices should be considered strict liability is still needed. As of September 2019, a decision has yet to be made.

    Johnson & Johnson
    Johnson & Johnson (J&J), a multi-national manufacturer of medical devices, pharmaceuticals, and consumer goods, has found itself involved in several lawsuits over defects in their medical devices. The medical devices division of J&J is split into several units, two of which are DePuy and Ethicon. In 2013, the DePuy unit of J&J was ordered to pay over $4 billion to resolve more than 7,500 over defective hip replacement implants. In another case, a federal jury in West Virginia awarded one woman $3.27 million after over 33,000 lawsuits were filed against the Ethicon unit of J&J for defective transvaginal mesh devices. Both cases addressed corporate negligence, strict liability, and product liability issues.

    Riegel v. Medtronic
    In 1996, patient Charles Riegel underwent angioplasty when a Medtronic heart catheter burst during the procedure, forcing him to undergo emergency bypass surgery as a result. Reigel sued Medtronic, alleging negligence in the design, manufacture and labeling of the catheter, strict liability, and breach of express and implied warranties. Medtronic sought summary judgment on the basis that the claims were preempted since the FDA had approved use of the catheter under the premarket approval process. The district court granted summary judgment for most of Riegel’s claims and the Second Circuit affirmed the district court decision. Medtronic and other medical device manufacturers, backed by the federal government, also argued that the federal system should bar state law claims. Reigel contended that the FDA’s approval process had been sloppy and inadequate. In 2008, the Supreme Court, in an 8-1 decision, held in favor of the manufacturer, finding that Congress intended that the pre-market approval process at issue in Riegel would bar the filing of suits.

    Medmarc Casualty Insurance Company v. Angeion Corporation
    Angeion Corporation, now known as MGC Diagnostics Corporation, discovered in 2002 that the batteries of their implantable cardioverter defibrillators were wearing out prematurely, so they withdrew these devices from the marketplace. Device distributors sought reimbursement from Angeion for incurred costs related to withdrawal of the defibrillators. Angeion and the distributors settled for $1.4 million. When Angeion sought coverage from its insurer Medmarc under a commercial general liability policy, Medmarc denied coverage and filed a declaratory judgement action. The court had previously held that Medmarc had a duty to defend and that they had breached the duty, but in this action the duty to indemnify was the issue and the applicability of exclusions in the CGL policy was a critical concern. Ultimately the court held that certain exclusions applied to some of the claims involving the failure of the product while in use, but not to claims where the defibrillators did not fail while in use. Specifically, the defibrillators that met the voltage level requiring recall failed while in use and were thus not subject to the exclusion, whereas the units that did not have a voltage level that warranted recall were subject to the exclusion and not covered by the policy. Other issues addressed in the decision included what constituted medical expenses, the reasonableness of the settlement, and the recovery of defense fees.

    Suter v. General Accident Insurance Company
    The decision in Suter v. General Accident Insurance Company, 2006 U.S. Dist. LEXIS 48209 (D. N.J. 2006), is a decision that was vacated after the parties settled, but provides a thorough analysis of important medical device insurance and reinsurance coverage issues. This case involved claims brought against Pfizer Inc. in connection with allegedly faulty Shiley heart valves. Pfizer paid hundreds of millions of dollars to claimants whose valves had not yet failed, but who contended that they suffered from anxiety about possible failure. Issues considered by the court included not only whether the anxiety claims should be allowed at all, but also how to set the date of injury trigger for all the claims, a determination critical to assessing whether the injuries occurred within the policy period.

    Future Outlook

    While advances in technology may eventually eliminate some of the current causes of liability involving today’s medical devices, new medical devices and enhancements in existing ones will inevitability spawn new product liability exposures. The demand for new health care products is continuing to rise and new technologies are making procedures less invasive and safer. Devices that depend on telemedicine, making them available for home use (such as devices that check heart rates and blood sugar levels), have gained popularity. While these devices and the use of telemedicine can lead to more effective and efficient health care, insurers must add user error and privacy issues to the already significant list of concerns.

    In the News

    2023

    • Medtronic recalls nearly 350,000 defibrillators for risk of reduced shock - Susan Kelly, MedTech Dive (07/18/2023)
      Medtronic is recalling 348,616 implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds) manufactured after July 2017 because the devices may deliver a reduced-energy shock, or no shock at all, when therapy is needed, the U.S. Food and Drug Administration said Tuesday.

    2022

    • Exela sodium bicarbonate injection recalled due to potential for flying glass - American Hospital Association, American Hospital Association (10/14/2022)
      Exela Pharma Sciences this week recalled 49 lots of sodium bicarbonate injection because the vial may break while preparing the product for administration, causing glass to fly. Exela has received five reports of injury from flying glass. The drug is used to treat metabolic acidosis.

       

    2020

    2019

    2018

    • FDA says it will overhaul criticized medical device system - MATTHEW PERRONE, AP News (11/26/2018)
      U.S. health officials said Monday they plan to overhaul the nation’s decades-old system for approving most medical devices, which has long been criticized by experts for failing to catch problems with risky implants and related products. . . . The Food and Drug Administration announced plans aimed at making sure new medical devices reflect up-to-date safety and effectiveness features. The system targeted by the actions generally allows manufacturers to launch new products based on similarities to decades-old products, not new clinical testing in patients. . . . The FDA’s move came one day after the publication of a global investigation into medical device safety by more than 50 media organizations, including The Associated Press. Led by the International Consortium of Investigative Journalists, the group found that more than 1.7 million injuries and nearly 83,000 deaths suspected of being linked to medical devices had been reported to the FDA over a 10-year period.
    • Supreme Court sets high bar for medical device lawsuits - Justin Pritchard, AP (11/25/2018)
      The tiny balloon was supposed to stretch open a blocked artery on Charles Riegel’s diseased heart. Instead, when the doctor inflated the balloon, it burst. . . . The patient went on life support but survived. His lawsuit against the manufacturer of that arterial balloon did not. . . . The U.S. Supreme Court ruled in favor of Medtronic, among the world’s largest makers of medical devices, setting a precedent that has killed lawsuits involving some of the most sophisticated devices on the market. . . . The device that harmed Riegel had cleared the U.S. Food and Drug Administration’s most rigorous review, known as “pre-market approval.” To reach consumers, Medtronic provided regulators with documentation that the Evergreen Balloon Catheter would be safe and effective. . . . In Riegel v. Medtronic Inc., the justices grappled with whether Medtronic had any liability. They ruled that devices that have received pre-market approval are effectively immune from product liability lawsuits in state courts, where juries can award huge sums. The reasoning: Congress wrote that states couldn’t add safety requirements beyond what the FDA imposes.
    • Medtronic disables pacemaker programmer updates over hack concern - Reuters (10/11/2018)
      Medical device maker Medtronic Plc has disabled internet updates for some 34,000 CareLink programming devices that healthcare providers around the world use to access implanted pacemakers, saying the system was vulnerable to cyber attacks.
    • Medical device recalls reach historic levels in 2018 with software as leading cause - Evan Sweeney, FierceHealthcare (05/09/2018)
      Medical device recalls reached record highs in the first three months of 2018 thanks to software complications that are likely to continue with the proliferation of high-tech devices. . . . Device recalls increased 126% in the first quarter of 2018. At 343 recalls, it was the highest number in a single quarter since 2005, according to a report by Stericycle’s Recall Index (PDF), which tracks recall data across several industries. . . . Software was the biggest driver of medical device recalls in the first quarter, accounting for 23% of all recalls. Software issues have been the leading factor in device recalls each quarter since the beginning of 2016.

    2017

    • Robot-surgery firm from Sunnyvale facing lawsuits, reports of death and injury - ETHAN BARON, The Mercury News (10/22/2017)
      When Teresa Hershey was told she needed a hysterectomy, her doctor recommended a novel approach: an operation performed by a robot, guided by the surgeon. . . . Now, seven years and 10 corrective surgeries later, Hershey is gearing up to fight Intuitive in Santa Clara County Superior Court. She says she has refused the firm’s offers to settle. . . . Since the da Vinci surgical robot received FDA approval in 2000, Intuitive’s devices — which are operated by a surgeon using joysticks, foot pedals and a 3-D viewer — have propelled the firm to a $35 billion valuation and world dominance in robot-aided surgery. But the legal claims that have come with Intuitive’s success showcase the serious risks that accompany the rewards new medical technology can bring. . . . In a 2014 regulatory filing, Intuitive said it was facing 3,000 product-liability claims over surgeries taking place between 2004 and 2013 when its robots performed about 1.7 million procedures. . . . The robots perform a variety of surgeries, including gynecological, cardiac, urologic and colorectal, according to the company. . . . Hershey, a mother of two adult children who lives near Palm Springs and owns a garage door company with her husband, felt fine after her hysterectomy, spending a night in the hospital and returning home the next day. Severe, stabbing pain started that night, and she was taken by ambulance to the hospital, she said. After more than a week of tests, scans and examinations, Hershey was left with “a lot of pain and no answers.” . . . . Her surgeon advised another surgery to find out what was wrong, and it turned out that what was wrong appeared to be the same thing that many other da Vinci patients cited in claims and lawsuits: She had damage to an internal organ; in her case, a hole in her bowel. . . . So far, just two lawsuits against Intuitive over the da Vinci robots have gone to trial.
    • Changes to high-risk medical devices often supported by low-quality research - University of California - San Francisco, Science Daily (09/15/2017)

      Clinical trials that test changes in the design or use of high-risk medical devices are often poorly designed, and can rely on inadequate or potentially biased data, according to a new study by researchers at the UC San Francisco and Yale School of Medicine. . . . In the study, published August 15, 2017 in JAMA, the authors reviewed clinical trials supporting U.S. Food and Drug Administration (FDA) approval of changes to high-risk devices over the last decade. They found that fewer than half of these studies were randomized, blinded, or controlled -- the "gold standards" for clinical trials of drugs.

    • Hacking risk leads to recall of 500,000 pacemakers due to patient death fears - Alex Hern, The Guardian (08/31/2017)

      Almost half a million pacemakers have been recalled by the US Food and Drug Administration (FDA) due to fears that their lax cybersecurity could be hacked to run the batteries down or even alter the patient’s heartbeat. . . . The recall won’t see the pacemakers removed, which would be an invasive and dangerous medical procedure for the 465,000 people who have them implanted: instead, the manufacturer has issued a firmware update which will be applied by medical staff to patch the security holes.

    • 465,000 Pacemakers Recalled on Hacking Fears, Chris Morris, Fortune - Chris Morris, Fortune (08/31/2017)
      The Food and Drug Administration is alerting people to a voluntary recall of 465,000 pacemakers after security vulnerabilities were discovered that could let hackers reprogram the devices, potentially putting patient lives at risk. . . . Several devices from Abbott (formerly known as St. Jude Medical) are included in the recall, which the FDA says is intended as a “corrective action”, including the Accent, Anthem, Accent MRI, Accent ST, Assurity, and Allure. . . . The good news: If you’re affected by the recall, you won’t have to have the pacemaker removed and replaced. (In fact, the FDA recommends against that.) Officials say the vulnerability can be fixed with an upgrade to the device’s firmware, something that takes just three minutes or so to complete. (While the system is updating, the device will work in backup mode, ensuring its essential features remain in operation.)
    • Surgical device that spread cancer is revamped, but safety is questioned - Marie McCullough, Philly.com (08/13/2017)

      Olympus America Inc. is moving ahead with efforts to revamp the electric morcellator, a gynecological surgical device that has been largely abandoned because it can spread a hidden uterine cancer. . . . Power morcellators typically have spinning blades that enable doctors to mince and then remove a uterus or uterine fibroids through tiny incisions, making recovery faster than with traditional cut-open-the-belly operations. But in rare cases — the U.S. Food and Drug Administration estimates 1 in 350 — morcellation hurls bits of an undetected uterine sarcoma around the woman’s abdomen, worsening her prognosis. . . . Late last year, Olympus introduced its new “contained tissue extraction system,” which combines a morcellator with a bag intended to prevent cells from escaping. But the FDA requires the product information to warn that it “has not been clinically demonstrated to reduce the risk” of spreading cancer, and that morcellation is not appropriate in most cases.

    • Japanese maker of medical scopes hit with $6.6 million verdict in superbug case - BEN SCHMITT, TribLive (07/25/2017)

      A Washington jury this week issued a $6.6 million verdict against medical scope maker Olympus Corp. in connection with a deadly superbug outbreak. . . . Jurors ordered Olympus to pay the money to a Seattle hospital, and also ruled that the hospital should pay $1 million to family members of a patient who died there, according to a Kaiser Health News report. . . . The verdict came after an eight-week trial, the first in the United States related to gastrointestinal scopes causing outbreaks of drug-resistant infections.

    • F.D.A. Deal Would Relax Rules on Reporting Medical Device Problems - SHEILA KAPLAN, New York Times (07/11/2017)

      Makers of cardiac defibrillators, insulin pumps, breast implants and other medical devices might be able to delay reporting dangerous malfunctions to the Food and Drug Administration under an agreement heading for a vote in Congress. .  . . Device makers will still have to quickly report any injuries or deaths related to their products. They would have more time, though, to file reports on devices that may not be working properly, and have the potential for injury.

    • Australian class-action case opens over pelvic mesh implants - Kristen Gelineau, Associated Press, ABC News (07/04/2017)
      More than 700 Australian women in a class-action case against pharmaceutical giant Johnson & Johnson that started Tuesday argued that the company's vaginal mesh implants caused them devastating pain, ravaged their bodies and, in some cases, ruined their lives.
    • Jury Returns $454M Fraud Verdict in Hospital Gown Lawsuit - The Associated Press, US News (04/10/2017)

      Kimberly-Clark and its spinoff medical technology firm Halyard Health have been hit with $454 million in compensatory and punitive damages, after a federal jury found the companies misled California buyers about the impermeability of their MicroCool surgical gowns. Jurors in Los Angeles returned the verdict Friday in a class-action lawsuit brought by more than 400 hospitals and health centers in California. The lawsuit claimed the gowns were falsely represented as providing protection against serious diseases.

    • Device-maker expands recall of Mylan EpiPen, EpiPen Jr. to include U.S. - Doug G. Ware, UPI (03/31/2017)
      Meridian Medical Technologies, a manufacturer of Mylan's EpiPen auto-injectors, has expanded a recent voluntary recall to include some of the life-saving medical devices in the United States, officials said Friday. Mylan's original March 20 recall affected about 80,000 of the EpiPen devices shipped to locations outside the United States. 
    • University of Minnesota study finds companies inclined to wait too long to recall medical devices - Joe Carlson, Star Tribune (02/18/2017)
      Medical device companies, like the hundreds that dot Minnesota, do not know everything about the safety of their products. . . . The Food and Drug Administration requires device makers to prove new devices are safe to use as directed, but there’s only so much testing the agency can require before approving or denying a new product for market. That’s why the FDA requires “postmarket” surveillance, which includes investigating all complaints about their devices and reporting confirmed problems publicly. . . . But researchers and regulators say the device-surveillance system is deeply flawed, exposing patients and doctors to greater risks. . . . Many device problems are never logged in the FDA’s public system for adverse-event reporting known as MAUDE. And a study published last month by University of Minnesota researchers found that even when device companies do have the relevant information at hand, they are often biased in favor of waiting too long to issue product recalls.

    2016

    • FDA rules allow medical device makers to keep injuries under wraps - Joe Carlson and Jim Spencer, Star Tribune (10/16/2016)
      Makers of medical devices, from heart valves to drug pumps, are required to tell the U.S. Food and Drug Administration whenever they learn that a product may have injured someone. Those reports are usually available to patients and their doctors. But a Star Tribune analysis of recently obtained data shows that the FDA has accepted late reports that cover hundreds of thousands of incidents, sometimes years after the fact, and has created a program that lets device makers keep the details out of view. For example, the FDA let Illinois-based Baxter International put 75,000 unreported malfunctions of its Colleague drug pump into a confidential report while publicly disclosing only a single, brief summary.
    • Whistleblower case contends surgical device maker misled FDA — and patients paid the price - SHEILA KAPLAN, STAT (08/15/2016)

      In 2009, Lew went to UCLA Medical Center for surgery to relieve numbness and pain in his hands. The operation appeared to be a success. But he later began having trouble speaking. His left eye drooped. He developed severe nerve pain and weakness in his neck, arms, and hands. . . . In July, Lew, 52, settled with the University of California for $4.2 million; the manufacturer of the device, Medtronic, also settled for a confidential amount. Both parties denied any wrongdoing. . . .  Yet the legal challenge is not over for Medtronic. The company, one of the world’s largest medical device manufacturers, now faces a whistleblower lawsuit that claims it sought Food and Drug Administration approval for its devices under false pretenses — and that the devices have been regularly used for a purpose that was never intended by regulators.

    • IBM big data used for rapid diagnosis of rare leukemia case in Japan - TOMOKO OTAKE, Japan Times (08/11/2016)

      In a possible first in Japan, doctors have used artificial intelligence to diagnose a rare type of leukemia and identify life-saving therapy far faster than if they had examined the genetic data manually. . . . To find out more about the cause of her illness, the researchers supplied the woman’s genetic data, and Watson cross-checked it with the database, detecting gene mutations that are unique to a particular type of leukemia.

    • FDA retreats from recall of scope-cleaning machines - Chad Terhune, Los Angeles Times (05/06/2016)
      The Food and Drug Administration has dropped a recall of some 2,800 scope-cleaning machines in use at hospitals and clinics nationwide despite a finding by a top agency scientist last year that the action was “necessary to protect public health.”
    • Why it took years for the FDA to warn about infections tied to medical scopes - Melody Peterson, LA Times (02/08/2016)
      An outbreak at a Pennsylvania hospital in late 2012 should have been an early warning that a reusable medical scope was spreading deadly infections and nearly impossible to disinfect... But staff at the federal Food and Drug Administration lost the report, one of multiple missteps that allowed doctors and hospitals to continue using the scope for three more years even as dozens of patients were sickened.
    • Olympus to recall and redesign medical scope linked to superbug outbreaks - Melody Petersen, LA Times (01/15/2016)
      Olympus Corp. said Friday that it would voluntarily recall and redesign a troubled medical scope that has been linked to deadly patient infections around the world.
    • Affected hospitals left in dark on device maker violations - David Weissman, York Dispatch (01/01/2016)
      The FDA identified multiple issues with the new cleaning process of a device linked to deadly infections in local heart surgery patients, but the area hospitals involved weren't notified of the violations for more than four months.

    2015

    • Lawmaker asks SEC to investigate Olympus over failure to disclose outbreak report - Chad Terhune and Melody Petersen , LA Times (12/21/2015)
      A U.S. lawmaker is calling on the SEC to investigate Olympus Corp. in response to a Times article that detailed how the company kept selling its scopes despite warnings from a 2012 superbug outbreak in the Netherlands.
    • FDA orders recall of 2,800 scope-washing machines, citing infection risk - Chad Terhune, LA Times (11/13/2015)
      Amid an ongoing investigation into superbug outbreaks nationwide, U.S. regulators have ordered a Pennsylvania company to recall its scope-cleaning machines used at UCLA and more than 1,000 other hospitals and clinics.
    • FDA warns about infections from another type of medical - Chad Terhune, LA Times (09/17/2015)
      Federal regulators expanded their warnings about medical scopes spreading infections, issuing a new alert Thursday about contaminated bronchoscopes posing a risk to patients.
    • GAO to investigate medical device implicated in cancers - Marie McCullough, The Inquirer (09/05/2015)
      The U.S. Government Accountability Office has agreed to investigate why an electric device used in gynecological surgery was marketed for two decades before safety warnings were issued by the Food and Drug Administration.
    • Serious infections tied to medical scopes go far beyond issues with a single device - MELODY PETERSEN, LA Times (08/02/2015)
      A doctor reported in December that a medical scope commonly used to examine patients' lungs had infected 14 people with a superbug that kills half its victims.
    • House Passes Bill to Improve Safety Monitoring of Medical Devices - Jennifer Levitz , The Wall Street Journal (07/12/2015)
      A sweeping medical research bill that passed the House on Friday included a provision aimed at improving safety monitoring of medical devices—an amendment inspired by a controversial gynecological device.
    • $100M Verdict Rocks Boston Scientific - Marie Szaniszlo, Boston Herald (05/28/2015)
      A stinging, $100 million verdict yesterday against Boston Scientific Corp. in a case involving inserts it makes to treat incontinence in women is unlikely to cause lasting damage to the state’s largest medical device company, but could force it to consider settling thousands of other product-liability lawsuits, according to one analyst.
    • Scrutiny of How Medical-Device Companies Sell Products Heats Up - Joe Carlson, Star Tribune (05/08/2015)
      The Justice Department is ramping up scrutiny of device companies just as the Food and Drug Administration is tinkering with its rules on marketing.
    • New machine could one day replace anesthesiologists - Todd C. Frankel, The Washington Post (05/01/2015)
      The new machine that could one day replace anesthesiologists sat quietly next to a hospital gurney occupied by Nancy Youssef-Ringle. She was nervous. In a few minutes, a machine — not a doctor — would sedate the 59-year-old for a colon cancer screening called a colonoscopy.
    • Motion accuses pelvic mesh lawyers of aggressive recruiting - Kyla Asbury, West Virginia Record (01/15/2015)
      A motion alleging plaintiffs’ attorneys have been fraudulent in their aggressive recruitment of clients for pelvic mesh litigation has been filed in a MDL lawsuit against Ethicon and Johnson & Johnson.

    2014

    • A true helping hand - AP, Sun Chronicle (10/09/2014)
      Scientists are moving closer to an artificial hand that can feel: Implanted electrodes allowed some amputees to tell by touch how gently to grasp, letting them pluck fruit without crushing it.
    • How medical tech promises to save lives - Daniela Hernandez , Kaiser Health News, USA Today (06/16/2014)
      To be sure, computers can't replace doctors at the bedside, but they can be a tool to take full advantage of electronic medical records, transforming them from mere e-filing cabinets into full-fledged doctors' aides that can deliver clinically relevant, high-quality data in real time.
    • DePuy to Pay $2.5 Billion in Implant Suits - Stephen Levy, QMed (05/27/2014)
      DePuy Orthopaedics, a Warsaw, IN- based subsidiary of Johnson& Johnson, has informed Judge David Katz, US District Court, Northern District of Ohio, that it has waived its right to walk away from the settlement agreement covering thousands of DePuy ASR hip implant product liability lawsuits reached last November.
    • Coloplast Said to Pay $16 Million to Settle Mesh Lawsuits - Jef Feeley, Bloomberg News (03/04/2014)
      Coloplast A/S, the Danish maker of medical products, agreed to pay about $16 million to settle lawsuits accusing it of injuring women with its vaginal-mesh inserts, three people familiar with the accord said.

    2011

    • FDA process hampers medical devices innovation, study says - Janet Moore, Seattle Times (05/26/2011)
      When it comes to the newest and most-advanced medical devices, Europe is getting them first, according to a study released this week by a group of researchers at Northwestern University in Chicago.

    Additional Items

    By far and away the most well rounded and useful Cat-focused industry conference out there. Perfect for all levels within the industry. From the conference content, the presenters and the attendees, this conference is a can’t miss for those interested in expanding their knowledge and learning more about cat related insurance and reinsurance modeling topics Nick DiMuzio, Everest

    "Fantastic, enriching conference - brilliantly planned and run, illuminating talks and excellent opportunities for networking across multiple areas of catastrophic risk.” Gary Ackerman, University at Albany

    “From a treaty underwriter's point of view, RAA presented relevant topics related to today's macro events. Scientific presentations provided insight that I can incorporate in underwriting and share with my clients.” Eric B. Silberman, Munich Re

    "Great conference with some of the biggest names in the business presenting their work. What more could you ask for?” Ron Nash, Nash Consulting

    “A perfect introduction to the world of reinsurance. Relevant topics, great speakers and the opportunity to network with industry peers makes this a must go event.”
    Tom Barrett, Everest Re

    Demystifying Reinsurance was an excellent tool to clearly understand and break down the basics. Very good class and recommend it for beginners and even as a refresher course for the intermediate student.”
    Chenessia West, TransRe

    “Re Basics is the ideal opportunity whether an industry professional or student of insurance to understand the in and outs of reinsurance while being able to network with persons spread across the whole industry.”
    Darius Zuill, Bermuda Monetary Authority

    “This has been the best reinsurance seminar that I have been to! Whether a reinsurance seasoned vet or new to the field, this is an engaging seminar that addressed specific issues of the reinsurance market.”
    Michelle Thimm, Church Mutual Insurance 

    “Re Underwriting provided a comprehensive and interesting overview of underwriting in the current market with a major (and interesting) focus on trends. Very useful for underwriting and non-underwriting alike.”
    DeVika Bourne, PartnerRe

    “Very informative experience, and a great way to keep up to date on current underwriting events and trends.”
    Steven Whalen, Aspen Re

    “Time well spent in learning the updated underwriting business and networking!”
    Christine Chen,  Everest Re 

    “The panels and presentations were thought provoking and fascinating as numerous topics were covered affecting the industry. I’m leaving the conference with a greater insight of the future market.”
    Brittany de Frias, AXIS Capital 

     

    “RAA Re Finance was the first RAA seminar I attended, and I was thoroughly impressed with the speakers and content. I learned a great deal from the presentations and intend to bring some new ideas back to my company and share with the team!”
    Taylor Robinson, ICW Group

    “Fantastic slate of instructors who thoughtfully walked us through financial reporting and other aspects of reinsurance finance. They used terminology that non finance people (lawyers) could understand. Really great program.”
    Steven Bazil, The Bazil Group

    “If you are in Reinsurance Accounting/Finance, you need to take this course to help you with your job.”
    Frank Borawski, Markel  

    “The speakers were excellent! There is something to be said about a person, and in this case a group of people, who can take time away from their busy schedules and explain to everyone something they feel passionate about in a manner that's understandable. My only complaint is that I wish we had more time with them.”
    Jessica Mieles, Sompo International

    “The RAA ReContracts is the most comprehensive reinsurance contract wording training available in the U.S. market.”
    David Kragseth, Guy Carpenter   

    “The course was very helpful in addressing different viewpoints and important things to consider in contract design and review.”
    Andy Martin, AmericanAg 

    “The RAA contract course was very informative and interesting. It covered a wide range of Reinsurance Contracts Types. In my Reinsurance Career, I have had the opportunity to work on a limited type of contracts, so I learned a lot.”
    Vivian Castro, Arch Insurance Company 

    “The RAA Contracts course provides the opportunity to engage with relevant topics, taught by industry experts, in both seminar and small group environments. The course material and industry experts provide an understanding on a wide range of subjects.” 
    Kevin English, LMRe

    “Participation in Re Claims should be mandatory for all P&C reinsurance underwriters. It’s truly an eye-opener, providing an in-depth look from a claims manager’s perspective on what happens to the business that we underwrite. There are lots of do’s and don’ts to pay attention to. Re Claims answers all the hard questions."  Michael Delacruz, China Re P&C

    “I absolutely love this program. I learned so many new things. Reinsurance from the industry’s top executives, interactive activities, interesting panels, and innovating presentations makes for an intriguing few days. Well worth the time and money.” Chenessia West, TransRe

    “As a reinsurance attorney I find Re Claims highly valuable to stay abreast of emerging issues. Also, being walked through practical case studies is extremely helpful in creating a thorough understanding of how contracts work.” Steven Bazil, The Bazil Group

    Become a Re Scholar!

    The Re Ed Institute's Re Scholar Program seeks to recognize those who achieve a high standard of reinsurance education by completing the Re Scholar curriculum. Learn More.


    Become a Re Ed Sponsor

    The RAA’s Reinsurance Education Institute programs attract professionals from the world’s leading insurance/reinsurance companies, brokers, law firms and consulting firms. Interested in sponsoring? Contact Carolyn Fahey.